Weathers Shiao-Pei, Gilbert Mark R
Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 431, Houston, TX, 77030, USA,
J Neurooncol. 2015 Jul;123(3):331-7. doi: 10.1007/s11060-015-1716-2. Epub 2015 Jan 11.
Immune system modulation is evolving into a promising treatment modality in glioblastoma. Our growing understanding of glioma immunobiology has fueled efforts to develop immunotherapeutic strategies to combat this lethal primary brain tumor. Autologous stimulated lymphocytes, immunotherapy with cytokines and dendritic cells, immune checkpoint inhibitors, virotherapy, and tumor or peptide based vaccines are immunotherapy approaches under active investigation. A number of challenges are evident in the design of immunotherapy clinical trials in glioblastoma including patient selection, immune and imaging response monitoring, and evaluation of clinical outcome.
免疫系统调节正逐渐成为胶质母细胞瘤一种有前景的治疗方式。我们对胶质瘤免疫生物学的不断深入了解推动了对抗这种致命原发性脑肿瘤的免疫治疗策略的研发。自体刺激淋巴细胞、细胞因子和树突状细胞免疫疗法、免疫检查点抑制剂、病毒疗法以及肿瘤或肽基疫苗都是正在积极研究的免疫治疗方法。胶质母细胞瘤免疫治疗临床试验的设计中存在一些明显的挑战，包括患者选择、免疫和影像反应监测以及临床结果评估。
